- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07643220
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions
An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of "AJU-G721" and "G721R" in Healthy Adult Male Subjects
To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, South Korea
- Bumin Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male adults aged ≥19 years and <55 years at screening.
- Body weight ≥ 50 kg and body mass index (BMI) between 18 and 30 kg/m².
- Clinically healthy based on medical history, physical examination, ECG, and laboratory test results, as determined by the investigator.
- Willing and able to provide written informed consent.
- Agrees to use medically acceptable contraception during the required study period.
Exclusion Criteria:
- Use of medications known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or other medications that may interfere with the study within 10 days prior to dosing.
- Participation in another clinical trial involving an investigational product within 6 months prior to the first dose.
- Whole blood donation within 8 weeks or component blood donation within 2 weeks prior to the first dose.
- History of gastrointestinal resection that may affect drug absorption.
- Known hypersensitivity to dutasteride, tamsulosin, or any component of the investigational product.
- History of psychiatric illness, or any condition considered unsuitable for study participation by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Sequence A
Period 1: Reference Drug, Single dose/ Period 2: Test Drug, Single dose |
AJU-G721 G721R |
|
Experimental: Sequence B
Period 1: Test Drug, Single dose/ Period 2: Reference Drug, Single dose |
AJU-G721 G721R |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax of Dutasteride and Tamsulosin.
Time Frame: [Time Frame: 0 hour ~ 72 hour after drug administration]
|
To assess the maximum observed plasma concentration (Cmax) of Dutasteride and Tamsulosin. |
[Time Frame: 0 hour ~ 72 hour after drug administration]
|
|
AUCt of Dutasteride and Tamsulosin
Time Frame: [Time Frame: 0 hour ~ 72 hour after drug administration]
|
To assess the plasma concentration-time curve from time 0 to the last measurable concentration (AUCt) of Dutasteride and Tamsulosin |
[Time Frame: 0 hour ~ 72 hour after drug administration]
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 25BPH11801
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.